Abstract
Compounds of the trace element vanadium have been shown to mimic insulin in in vitro and in vivo systems. These compounds have been found to exert anti-diabetic effects in rodent models of type 1 and type 2 diabetes mellitus as well as in a limited number of studies in human diabetic subjects. Thus, vanadium compounds have emerged as agents for potential use in diabetes therapy. However, treatment of diabetic animals with inorganic vanadium salts has also been associated with some toxic side-effects such as gastrointestinal discomfort and decreased body weight gain. In addition, vanadium salts have been reported to exert toxic effects on the liver and kidney. More recently, it was shown that organic vanadium compounds were much safer than inorganic vanadium salts and did not cause any gastrointestinal discomfort, hepatic or renal toxicity. This review briefly summarizes the anti-diabetic and toxic effects of vanadium compounds.
Similar content being viewed by others
References
Chasteen ND: The biochemistry of vanadium. In: Structure and Bonding. Springer Verlag, Berlin, Heidelberg, 1983, pp 105-138
Srivastava AK: Potential use of vanadium compounds in the treatment of diabetes mellitus. Exp Opin Invest Drugs 4: 525-536, 1995
Lyonnet B, Martz M, Martin E: L'emploi thérapeutique des dérivés du vanadium. La Presse Médicale 32: 191-192, 1899
Tolman EL, Barris E, Bums M, Pansini A, Partridge R: Effects of vanadium on glucose metabolism in vitro. Life Sci 25: 1159-1164, 1979
Shechter Y: Insulin-mimetic effects of vanadate. Possible implications for future treatment of diabetes. Diabetes 39: 1-5, 1990
Heyliger CE, Tahiliani AG, McNeill JH: Effect of vanadate on elevated glucose and depressed cardiac performance of diabetic rats. Science 227: 1474-1477, 1985
Brichard SM, Lederer J, Henquin J-C: The insulin-like properties of vanadium: A curiosity or a perspective for the treatment of diabetes? Diabetes Metab 17: 435-440, 1991
Poucheret P, Verma S, Grynpas MD, McNeill JH: Vanadium and diabetes. Mol Cell Biochem 188: 73-80, 1998
McNeill JH, Yuen VG, Hoveyda HR, Orvig C: Bis(maltolato)-oxovanadium (IV) is a potent insulin mimic. J Med Chem 35: 1489-1491, 1992
Posner BI, Faure R, Burgess JW, Bevan AP, Lachance D, Zhang-Sun G, Fantus IG, Ng JB, Hall DA, Lum BS, Shaver A: Peroxovanadium compounds: A new class of potent phosphatase inhibitors which are insulin mimetics. J Biol Chem 269: 4596-4604, 1994
Shisheva A, Ikonomov O, Shechter Y: The protein tyrosine phosphatase inhibitor, pervanadate, is a powerful antidiabetic agent in streptozotocin-treated diabetic rats. Endocrinology 134: 507-510, 1994
Karasik A, Hattori M: Use of animal models in the study of diabetes. In: C.R. Kahn, G.C. Weir (eds). Jolin's Diabetes Mellitus. Lea and Febiger, Philadelphia, 1994, pp 317-350
Meyerovitch J, Farfel Z, Sack J, Shechter Y: Oral administration of vanadate normalizes blood glucose levels in streptozotocin-treated rats. J Biol Chem 262: 6658-6662, 1987
Gil J, Miralpeix M, Carreras J, Bartrons R: Insulin-like effects of vanadate on glucokinase activity and fructose 2,6-bisphosphate levels in the liver of diabetic rats. J Biol Chem 263: 1868-1871, 1988
Brichard SM, Okitolonda W, Henquin JC: Long term improvement of glucose homeostasis by vanadate treatment in diabetic rats. Endocrinology 123: 2048-2053, 1988
Blondel O, Bailbe D, Portha B: In vivo insulin resistance in streptozotocindiabetic rats-evidence for reversal following oral vanadate treatment. Diabetologia 32: 185-190, 1989
Bendayan M, Gingras D: Effects of vanadate administration on blood glucose and insulin levels as well as on the exocrine pancreatic function in streptozotocindiabetic rats. Diabetologia 32: 561-567, 1989
Ramanadham, S, Mongold J-J, Brownsey RW, Cros GH, McNeill JH: Oral vanadyl sulfate in treatment of diabetes mellitus in rats. Am J Physiol 257: H904-H911, 1989
Bollen M, Miralpeix M, Ventura F, Toth B, Bartrons R, Stalmans W: Oral administration of vanadate to streptozotocin-diabetic rats restores the glucose-induced activation of liver glycogen synthase. Biochem J 267: 269-271, 1990
Strout HV, Vicario PP, Biswas C, Superstein R, Brady EJ, Pilch PF, Berger J: Vanadate treatment of streptozotocin diabetic rats restores expression of the insulin responsive glucose transporter in skeletal muscle. Endocrinology 126: 2728-2732, 1990
Sekar N, Kanthasamy A, William S, Subramanian S, Govindasamy S: Insulin actions of vanadate in diabetic rats. Pharmacol Res 22: 207-217, 1989
Sakurai H, Tsuchiya K, Nukatsuka M, Sofue M, Kawada J: Insulin-like effects of vanadyl ion in streptozotocin-induced diabetic rats. J Endocrinol 126: 451-459, 1990
Pugazhenthi S, Khandelwal RL: Insulin-like effects of vanadate on hepatic glycogen metabolism in nondiabetic and streptozotocin-induced diabetic rats. Diabetes 39: 821-827, 1990
Rossetti L, Laughlin MR: Correction of chronic hyperglycemia with vanadate, but not with phlorizin, normalizes in vivo glycogen repletion and in vitro glycogen synthase activity in diabetic skeletal muscle. J Clin Invest 84: 892-899, 1989
Venkatesan N, Avidan A, Davidson MB: Antidiabetic action of vanadyl in rats independent of in vivo insulin-receptor kinase activity. Diabetes 40: 492-498, 1991
Saxena AK, Srivastava P, Bacquer NZ: Effects of vanadate on glycolytic enzymes and malic enzyme in insulin-dependent and-independent tissues of diabetic rats. Eur J Pharmacol 216: 123-126, 1992
Madsen KL, Porter VM, Fedorak RN: Oral vanadate reduces Na(+)-dependent glucose transport in rat small intestine. Diabetes 42: 1126-1132, 1993
Valera A, Rodriguez-Gil JE, Bosch F: Vanadate treatment restores the expression of genes for key enzymes in the glucose and ketone bodies metabolism in the liver of diabetic rats. J Clin Invest 92: 4-11, 1993
Malabu. UH, Dryden S, McCarthy HD, Kilpatrick A, Williams G: Effects of chronic vanadate administration in the STZ-induced diabetic rat. The antihyperglycemic action of vanadate is attributable entirely to its suppression of feeding. Diabetes 43: 9-15, 1994
Pederson RA, Ramanadham S, Buchan AMJ, McNeill JH: Long-term effects of vanadyl treatment on streptozotocin-induced diabetes in rats. Diabetes 38: 1390-1395, 1989
Yuen VG, Orvig G, McNeill JH: Glucose lowering effect of a new organic vanadium complex, bis(maltolato)oxovanadium (IV). Can J Physiol Pharmacol 71: 263-269, 1993
Yuen VG, Orvig C, Thompson KH, McNeill JH: Improvement in cardiac dysfunction in streptozotocin-induced diabetic rats following chronic oral administration of bis(maltolato)oxovanadium (VI). Can J Physiol Pharmacol 71: 270-276, 1993
Reul BA, Amin SS, Buchet JP, Ongemba L-N, Crans DC, Brichard SM: Effects of vanadium complexes with organic ligands on glucose metabolism: a comparison study in diabetic rats. Br J Pharmacol 126: 4674-4677, 1999
Yale J-F, Lachance D, Bevan AP, Vigeant C, Shaver A, Posner BI: Hypoglycemic effects of peroxovanadium compounds in Sprague-Dawley and diabetic BB rats. Diabetes 44: 1274-1279, 1995
Brichard SM, Pottier AM, Henquin JC: Long term improvement of glucose homeostasis by vanadate in obese hyperinsulinemic fa/fa rats. Endocrinology 125: 2510-2516, 1989
Pugazhenthi S, Angel JF, Khandelwal RL: Long-term effects of vanadate treatment on glycogen metabolizing and lipogenic enzymes of liver in genetically diabetic (db/db) mice. Metabolism 40: 941-946, 1991
Meyerovitch J, Rothenberg P, Shechter Y, Bonner-Weir S, Kahn CR: Vanadate normalizes hyperglycemia in two mouse models of non-insulin-dependent diabetes mellitus. J Clin Invest 87: 1286-1294, 1991
Brichard SM, Bailey CJ, Henquin J-C: Marked improvement of glucose homeostasis in diabetic ob/ob mice given oral vanadate. Diabetes 39: 1326-1332, 1990
Yuen VG, Pederson RA, Dai S, Orvig C, McNeill JH: Effects of low and high dose administration of bis(maltolato)oxovanadium (IV) on fa/fa Zucker rats. Can J Physiol Pharmacol 74: 1001-1009, 1996
Goldfine AB, Simonson DC, Folli F, Patti M-E, Kahn CR: In vivo and in vitro studies of vanadate in human and rodent diabetes mellitus. Mol Cell Biochem 153: 217-231, 1995
Cohen N, Halberstam M, Shlimovich P, Chang O, Shamoon H, Rossetti L: Oral vanadyl sulfate improves hepatic and peripheral insulin sensitivity in patients with non-insulin-dependent diabetes mellitus. J Clin Invest 95: 2501-2509, 1995
Boden G, Chen X, Ruiz J, van Rossum DV, Turco S: Effects of vanadyl sulfate on carbohydrate and lipid metabolism in patients with non-insulin-dependent diabetes mellitus. Metabolism 45: 1130-1135, 1996
Halberstam M, Cohen N, Shlimovich P, Rossetti L, Shamoon H: Oral vanadyl sulfate improves insulin sensitivity in NIDDM but not in obese nondiabetic subjects. Diabetes 45: 659-666, 1996
Domingo JL, Gomez M, Sanchez DJ, Llobet JM, Keen CL: Toxicology of vanadium compounds in diabetic rats: The action of chelating agents on vanadium accumulation. Mol Cell Biochem 153: 233-240, 1995
Domingo JL, Gomez M, Llobet JM, Corbella J, Keen CL: Oral vanadium administration to streptozotocin-diabetic rats has marked negative side-effects which are independent of the form of vanadium used. Toxicology 66: 279-287, 1991
Oster MH, Llobet JM, Domingo JL, German JB, Keen CL: Vanadium treatment of diabetic Sprague-Dawley rats results in tissue vanadium accumulation and prooxidant effects. Toxicology 83: 115-130, 1993
Nechay BR, Nanninga LB, Nechay PSE, Post RL, Grantham JJ, Macara IG, Kubena LF, Phillips TD, Nielsen FH: Role of vanadium in biology. Fed Proc 45: 123-132, 1986
Al-Bayati MA, Giri SN, Raah OG: Time and dose response study of the effects of vanadate in rats: Changes in blood cells, serum enzymes, protein, cholesterol, glucose, calcium and inorganic phosphate. J Environ Pathol Toxicol Oncol 10: 206-213, 1990
Bishayee A, Cecchin F: Time course effects of vanadium supplement on cytosolic reduced glutathione level and glutathione S-transferase activity. Biol Trace Element Res 48: 275-285, 1995
Mongold JJ, Cros GH, Vian L, Tep A, Ramanadham S, Siou G, Diaz J, McNeill JH, Serrano JJ: Toxicological aspects of vanadyl sulphate on diabetic rats: Effects on vanadium levels and pancreatic b-cell morphology. Pharmacol Toxicol 67: 192-198, 1990
Sanchez MT, Domingo JL: Effects of vanadium on activity and learning in rats. Physiol Behav 63: 345-350, 1998
Wang H, Scott RE: Unique and selective mitogenic effects of vanadate on SV40-transformed cells. Mol Cell Biochem 153: 59-67, 1995
Faure R, Vincent M, Dufour M, Shaver A, Posner BI: Arrest at the G2/M transition of the cell cycle by protein tyrosine phosphatase inhibition: Studies on neuronal and glial cell line. J Cell Biochem 59: 389-401, 1995
Fantus IG, Tsiani E: Multifunctional actions of vanadium compounds on insulin signaling pathways: Evidence for preferential enhancement of metabolic vs. mitogenic effects. Mol Cell Biochem 182: 109-119, 1998
Djordjevic C: Antitumor activity of vanadium compounds. In: H. Sigel and A. Sigel (eds). Biological Systems, Vanadium and Its Role in Life. Marcel Dekker, New York, 1995
Cruz TF, Morgan A, Min W: In vitro and in vivo antineoplastic effects of orthovanadate. Mol Cell Biochem 153: 161-166, 1995
Liasko R, Kabanos TA, Karkabounas S, Malamas M, Tasiopoulas AJ, Stefanou D, Collery P, Evangelou A: Beneficial effects of a vanadium complex with cysteine, administered at low doses on benzo (alpha) pyrene-induced leiomyosarcomas in Wistar rats. Anticancer Res 18: 3609-3613, 1998
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Srivastava, A.K. Anti-diabetic and toxic effects of vanadium compounds. Mol Cell Biochem 206, 177–182 (2000). https://doi.org/10.1023/A:1007075204494
Issue Date:
DOI: https://doi.org/10.1023/A:1007075204494